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Abstract
Objective
To identify circulating microRNAs (miRNAs) linked to disease, disease stage, and disability in
MS across cohorts.
Methods
Samples were obtained from the Comprehensive Longitudinal Investigation of Multiple
Sclerosis (CLIMB, Boston, MA), EPIC (San Francisco, CA), AMIR (Beirut, Lebanon) as part
of the SUMMIT consortium, and Stockholm Prospective Assessment of Multiple Sclerosis
(Stockholm, Sweden) cohorts. Serum miRNA expression was measured using locked nucleic
acid–based quantitative PCR. Four groups were compared: (1) MS vs healthy control (HC),
(2) relapsing-remitting (RR) vs HC, (3) secondary progressive (SP) vs HC, and (4) RR vs SP.
AWilcoxon rank-sum test was used for the comparisons. The association between each miRNA
and the Expanded Disability Status Scale (EDSS) score was assessed using the Spearman
correlation coefficient. For each comparison, the p values were corrected for multiple com-
parisons using the approach of Benjamini and Hochberg to control the false discovery rate.
Results
In the CLIMB cohort, 5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-
5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy
individuals; among these, miR-484 remained significant after accounting for multiple compar-
isons (p = 0.01).When comparing RRMSwithHCs, hsa-miR-484 showed a significant difference
(p = 0.004) between the groups after accounting for multiple group comparisons. When SP and
HC were compared, 6 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-142-5p, hsa-miR-320a,
hsa-miR-320b, and hsa-miR-320c) remained significantly different after accounting for multiple
comparisons. Disability correlation analysis with miRNA provided 4 miRNAs (hsa-miR-320a,
hsa-miR-337-3p, hsa-miR-199a-5p, and hsa-miR-142-5p) that correlated with the EDSS during
the internal reproducibility phase. Among these, hsa-miR-337-3p was the most statistically sig-
nificant miRNA that negatively correlated with the EDSS in three of the MS cohorts tested.
Conclusions
These findings further confirm the use of circulating serum miRNAs as biomarkers to diagnose
and monitor disease status in MS.
Classification of evidence
This study provides Class III evidence that levels of circulating miRNAs identify patients with MS.
MORE ONLINE
Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
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MS is an autoimmune disorder that attacks the CNS.1,2 The
disease course of MS is extremely variable3,4; this diversity in
the disease phenotype is not well correlated with currently
used biomarkers; thus, there is an urgent need for efficacious
diagnostic assays for MS detection, prognostic measures of
disease progression, and treatment response.
Research on circulating biomarkers has yielded some
promising candidates for MS detection including glyco-
proteins, chemokines, antibodies, lipopeptides, and genetic
polymorphisms. More recently, microRNAs (miRNAs)
have been investigated as potential biomarkers in MS.5–8
miRNAs constitute particularly exciting biomarker candi-
dates because they are very stable molecules, and their
differential expression in circulating fluids (e.g., blood) has
been shown to correlate with many disease states, in-
cluding MS.5
Recently, our laboratory identified a set of serum miRNAs as
potential diagnostic MS biomarkers.9 Differential expression
of 7 miRNAs in MS vs healthy controls (HCs) was validated
during a 2-year comprehensive discovery and validation study.
In addition, we reported 10 miRNAs that significantly cor-
related with patient disability status as measured by the Ex-
panded Disability Status Scale (EDSS).9
In the current study, we tested the reproducibility of our previous
findings using patients with MS and HCs from the Compre-
hensive Longitudinal Investigation of Multiple Sclerosis
(CLIMB) cohort. In addition, we tested the transportability of our
results inMS samples collected from three other internationalMS
collections including the SUMMIT consortium (San Franciso
and Beirut) and the STOPMS II study (Stockholm).
This study design using patient samples frommultiple centers
(n = 259) was implemented to identify the most promising
serum miRNA biomarker candidates for MS diagnosis and
disability status.
Methods
Study design
The study involved multiple phases: (1) discovery, (2) vali-
dation, (3) reproducibility, and (4) transportability phases
(figure e-1, links.lww.com/NXI/A63). The first 2 phases of
the study have been described previously.9 These phases are
summarized as follows:
1. Discovery: 652 miRNAs were measured in participants
from 3 groups: RRMS (n = 7), SPMS (n = 9), and HC
(n = 20).9
2. Validation: based on the findings observed in the
discovery phase, 191 miRNAs were measured in
a larger validation set of participants from CLIMB
patients: RRMS (n = 29), SPMS (n = 19), and HC (n =
30), including an additional cohort of participants with
either other inflammatory diseases or other neurode-
generative diseases.9 This phase was used as the
training set for a multivariate approach using predictive
models.
3. Reproducibility phase: 73 miRNAs showing promise to
serve as biomarkers9 were further analyzed in a re-
producibility phase with RRMS (n = 24), SPMS (n = 18),
and HC (n = 30) from the CLIMB cohort. This phase
was used as the test set for the predictive models that
were designed in the validation (training phase).
4. Transportability phase: the 73 miRNAs from the
reproducibility phase were further analyzed in 3 external
cohorts with study participants from 3 MS centers
worldwide: RRMS (n = 91), SPMS (n = 33), and HC
(n = 58).
Patient selection
For the reproducibility phase, a new group of participants
from the CLIMB cohort was identified. In addition to this
new group of CLIMB participants, 3 external cohorts were
included in the study. The first cohort was from the
AUBMC-Multiple Sclerosis Interdisciplinary Research
cohort of the American University of Beirut Medical
Center—Abou Haidar Neuroscience Institute; 31 patients
with RRMS, 5 patients with SPMS, and 19 HCs were in-
cluded in the study. The second cohort was from the EPIC
(Expression/genomics, Proteomics, Imaging, Clinical)
cohort of the University of California at San Francisco10;
27 patients with RRMS, 7 patients with SPMS, and 26 HCs
were included in the study. The third cohort was from the
STOPMS II (Stockholm Prospective Assessment of
Multiple Sclerosis) cohort of Sweden; 33 patients with
RRMS, 21 patients with SPMS, and 13 HCs were included in
the study.
The demographic characteristics of all 4 cohorts are pro-
vided in table 1. None of the selected patients were on any
disease-modifying treatment at the time of sample
collection.
Glossary
AD = Alzheimer disease; AMIR = AUBMCMultiple Sclerosis Interdisciplinary Research; ALS = amyotrophic lateral sclerosis;
AUBMC = American University of Beirut Medical Center; AUC = Area under curve; AUCROC = area under the ROC curve;
CLIMB = Comprehensive Longitudinal Investigation of Multiple Sclerosis; EPIC study = Expression, Proteomics, Imaging,
Clinical study; FDR = false discovery rate; HC = healthy control; miRNA = microRNA; RA = rheumatoid arthritis; RR =
relapsing-remitting; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis;
STOPMS II = Stockholm Prospective Assessment of Multiple Sclerosis.
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Standard Protocol Approvals, Registrations,
and Patient Consents
Written informed consent was obtained from all patients,
and regional ethical committees approved the study
(CLIMB cohort, IRB Protocol No: 1999P010435; EPIC
cohort, IRB Protocol No: 10-00104; AMIR cohort, IRB
Protocol No: IM.SK1.01; and STOPMS II cohort, IRB
Protocol No: 2010/2:1).
Sample collection and storage
Blood samples were collected in glass red top serum vacu-
tainer tubes without additives (Becton, Dickinson and
Company, Franklin Lakes, NJ), and serum tubes were kept at
room temperature for 30–60 minutes. Each sample was
centrifuged at 2000 RPM for 10minutes to separate the serum
and then stored at −70°C until RNA extraction. Freezing of
the serum occurred within 2 hours of the blood draw. Serum
samples from the external cohorts were sent to Boston for
further processing.
RNA extraction and analysis
RNA was isolated using the miRCURY kit (Exiqon, Waltham,
MA) and converted to cDNA using a synthesis kit from
Exiqon following the manufacturer’s instructions. Prepared
cDNAs were stored at −20°C until use. LNA SYBR green–
based real-time PCR was used to detect the expression of
selected miRNAs (Exiqon). Normalization was performed
using the mean expression of the miRNAs with the best sta-
bility index, i.e., showing expression stability in our sample set.
NormFinder software was used to calculate the stability index.
We used 5 normalizing miRNAs (hsa-miR-484, hsa-miR-30e-
5p, hsa-miR-590-5p, hsa-let-7d-3p, and hsa-miR-15b-5p).
The formula used to calculate the normalized Cq values is as
follows: Normalized  Cq = average  Cq− assay   Cq.
Statistical analysis
In the CLIMB cohort, 4 groups were compared for each
miRNA: (1) all MS vs HC, (2) relapsing-remitting (RR) vs HC,
(3) secondary progressive (SP) vs HC, and (4) RR vs SP, and
a Wilcoxon rank-sum test was used for the comparisons. For the
Wilcoxon rank-sum test, participants that had no measured ex-
pression were assigned a value below the smallest available
measurement so that these participants had the smallest rank for
all analyses. In addition to the group comparisons, the associa-
tion between each miRNA and the EDSS score was assessed
using the Spearman correlation coefficient. For each compari-
son, the p values for miRNAs that passed validation were cor-
rected formultiple comparisons using the approach of Benjamini
and Hochberg11 to control the false discovery rate (FDR).
We also compared the miRNA expression level between the
groups using a proportional odds model to adjust for age and
sex. The proportional odds model is a generalization of the
Wilcoxon rank-sum test that allows adjustment for other
variables.
In addition to the individual miRNA comparisons, prediction
models were developed in the validation cohort (training set).
The prediction models were built using all miRNAs that were
in the same direction in the discovery and validation phases of
the study using best subset regression with 3 miRNAs in the
model. Three miRNAs were chosen, given the sample size
limitations in the validation set (training set). The models
were evaluated using the area under the ROC curve
(AUCROC) in both the validation cohort (training set) and
the reproducibility cohort (test set) to estimate the ability of
the model to discriminate between the 2 groups. The esti-
mated AUCROC from the reproducibility phase of the
CLIMB cohort provides a more reliable estimate because data
Table 1 Patient demographics
Relapsing-
remitting
MS
Secondary
progressive
MS
Healthy
controls
CLIMB
N 24 18 30
Age 32.4 (6.6) 56.4 (9.3) 45.4 (15)
Female 19 (0.792) 15 (0.833) 25 (0.833)
EDSS 0.6 (0.9) 5.5 (1.6)
DD in y 3.9 (2.4) 17.2 (5.9)
AMIR
N 31 5 19
Age 33.5 (10.2) 40.2 (7.8) 37.6
(11.2)
Female 21 (0.677) 2 (0.4) 12 (0.632)
EDSS 2.1 (1.2) 4.5 (1.4)
DD 4.6 (4.7) 15.2 (11)
EPIC
N 27 7 26
Age 37.6 (6.8) 52.7 (5.8) 45.5
(10.2)
Female 20 (0.741) 7 (1) 12 (0.462)
EDSS 1 (0.8) 5.1 (1.3)
DD 3.9 (2.4) 19 (6) —
STOPMS II
N 33 21 13
Age 33.1 (9.4) 43.2 (4.3) 30.9 (5.6)
Female 23 (0.697) 11 (0.524) 6 (0.462)
EDSS 1.66 (1.7) 5.3 (1.5)
DD 2.2 (3.4) 19.6 (5.2) —
Abbreviations: AMIR = AUBMC-Multiple Sclerosis Interdisciplinary Research
cohort; CLIMB = Comprehensive Longitudinal Investigation of Multiple
Sclerosis; DD = disease duration; EDSS = Expanded Disability Status Scale;
EPIC = Expression/genomics, Proteomics, Imaging, and Clinical cohort;
STOPMS II = Stockholm Prospective Assessment of Multiple Sclerosis.
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used in this set were not used in model building. In addition to
best subset regression, several other approaches were used to
build prediction models including stepwise selection, lasso,
decision trees, and random forests, and the predictive per-
formance of these approaches in our test set was assessed.
All analyses performed in the CLIMB cohort were completed
in the 3 additional MS centers’ cohorts during transportability
phase. The miRNAs that showed significant differential ex-
pression or a significant association with the EDSS in multiple
cohorts were identified. Furthermore, the AUCROC for each
of the predictive models built in the CLIMB validation cohort
(training set) was calculated for each external test set.
Data availability
Anonymized data not provided in the article because of
space limitation will be shared upon request of other qualified
investigators.
Results
Reproducibility of biomarkers in the
CLIMB cohort
The miRNAs that qualified the validation of the comparison
betweenMS and HC in the CLIMB cohort with p < 0.05 were
tested during the reproducibility phase (table 2). Five pre-
viously validated miRNAs, namely, hsa-miR-484, hsa-miR-
140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c,
showed a significant difference, and 1 miRNA remained sig-
nificant after accounting for multiple comparisons (hsa-miR-
484, p = 0.01). When multiple miRNAs were included in
a predictive model for MS vs HC, the miRNAs included were
hsa-let-7c-5p, hsa-miR-452-5p, and has-miR-484. The
AUCROC for this model in the validation cohort was 0.85,
whereas the AUCROC in the reproducibility phase was 0.70
(figure e-2, links.lww.com/NXI/A63). When the other model
building approaches were used, the AUCROC in the re-
producibility cohort ranged from 0.67 to 0.71.
The comparisons of the miRNAs between RR and HC are
provided in (table e-1, links.lww.com/NXI/A64). In this
comparison, only hsa-miR-484 showed a significant difference
(p = 0.004) between the groups after accounting for multiple
comparisons. When best subset regression was used to select
a model for this comparison, the miRNAs included in the
model were hsa-miR-15b-3p, hsa-miR-451a, and hsa-miR-
584-5p. The AUCROC for this model in the validation set
was 0.82, whereas the AUCROC in the reproducibility phase
was 0.68 (figure e-3, links.lww.com/NXI/A63). When the
other model building approaches were used, the AUCROC in
the validation ranged from 0.63 (decision tree) to 0.68 (best
subset regression).
When SP and HC were compared (table e-2, links.lww.com/
NXI/A64), 8 miRNAs were significantly different, and 6
miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-142-5p, hsa-
miR-320a, hsa-miR-320b, and hsa-miR-320c) were significantly
different after accounting for multiple comparisons. The
miRNAs included in the model selected by best subset re-
gression were hsa-let-7c-5p, hsa-miR-320a, and hsa-miR-
424-5p. The AUCROC for this model in the validation was
0.99, whereas the AUCROC in the reproducibility phase was
0.71 (figure e-4, links.lww.com/NXI/A63). When the other
model building approaches were used, the AUCROC in the
validation ranged from 0.71 (best subsets) to 0.75 (random
forests).
When RR and SP were compared (table e-3, links.lww.com/
NXI/A64), no previously validated miRNAs were significantly
different between the groups. When best subset regression was
used to build a model, the miRNAs included in the model were
hsa-miR134-5p, hsa-miR-337-3p, and hsa-miR-532-3p. The
AUCROC for this model in the validation was 0.93, whereas
the AUCROC in the reproducibility phase was 0.63 (figure e-5,
links.lww.com/NXI/A63). When the other model building
approaches were used, the AUCROC in the validation ranged
from 0.53 (decision tree) to 0.72 (lasso).
Table 2 Differential expression of significant miRNAs during the reproducibility phase (MS vs healthy controls)
miRNA
Reproducibility phase Regev et al., 2016
Number Expressed Mean Expression Fold Change
Wilcoxon
p value FDR value
Adjusted
p valuea
Wilcoxon
p valueMS HC MS HC MS:HC
hsa-miR-484 42 30 −0.38 −0.66 1.21 0.0004 0.01 <0.01 <0.01
hsa-miR140-5p 42 30 −2.76 −2.41 0.78 0.01 0.07 0.01 <0.01
hsa-miR-320a 42 30 1.62 1.3 1.25 0.02 0.08 0.02 <0.01
hsa-miR486-5p 42 30 2.67 2.04 1.55 0.02 0.08 0.01 <0.01
hsa-miR-320c 42 30 −2.51 −2.89 1.30 0.04 0.12 0.04 <0.01
Abbreviations: FDR = false discovery rate; HC = healthy control; miRNA = microRNA.
Fifteen miRNAs were tested, and hsa-miR-320b, hsa-miR-20a-5p, hsa-miR-25-3p, hsa-miR-365a-3p, hsa-miR-941, hsa-miR-584-5p, hsa-miR-143-3p, hsa-miR-
140-3p, hsa-let-7c-5p, and hsa-let-7g-5p were not significant during the reproducibility phase.
Fold change was calculated as 2(differences in mean).
a Adjusted p value from proportional odds model adjusting for age and sex.
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For the disability biomarkers, the miRNAs that were significantly
correlated with the EDSS in validation as published in Regev et al.
20169 were further measured in reproducibility phase cohort. We
found that 4 miRNA, hsa-miR-320b, hsa-miR-337-3p, hsa-miR-
199a-5p, and hsa-miR-142-5p (table 3), were significantly cor-
related with the EDSS in the reproducibility phase cohort.
Transportability of biomarkers in external
MS cohorts
When the additional cohorts were analyzed, a modest number
of miRNAs showed significant differential expression in the
same direction in multiple cohorts (table 4). For the com-
parison of MS and HC, 5 miRNAs were found to be
Table 3 Correlation of significant miRNAs in association with Expanded Disability Status Scale in the reproducibility
phase
miRNA
Reproducibility Phase Regev et al., 2016
Spearman estimate p Value FDR Spearman estimate p Value
hsa-miR-142-5p −0.31 0.05 0.17 −0.39 0.00
hsa-miR-199a-5p −0.34 0.03 0.17 −0.32 0.00
hsa-miR-320b 0.41 0.01 0.06
hsa-miR-337-3p −0.41 0.01 0.06 −0.34 0.00
Abbreviations: FDR = false discovery rate; miRNA = microRNA.
Fifteen miRNAs were tested, and hsa-miR-140-3p, hsa-miR-142-3p, hsa-miR-16-5p, hsa-miR-199a-3p, hsa-miR25-3p, hsa-miR27a-3p, hsa-miR301b, hsa-miR-
320a, hsa-miR-376b-3p, hsa-miR-486-5p, and hsa-miR-877-5p were not significant during the reproducibility phase.
Table 4 miRNAs showing significant association/differential expression during the transportability phase
miRNAs
Sites with significant differential expression in MS vs HC
hsa-let-7e-5p AMIR (p = 0.032), STOPMS II (p < 0.01)
hsa-let-7f-5p CLIMB (p = 0.05), STOPMS II (p = 0.002)
hsa-miR-486-5p CLIMB (p = 0.02), STOPMS II (p = 0.013)
hsa-miR-30e-5p CLIMB (p = 0.013), EPIC (p = 0.047)
Sites with significant differential expression in RR vs. HC
hsa-let-7e-5p AMIR (p = 0.031), STOPMS II (p = 0.002)
hsa-let-7f-5p CLIMB (p = 0.038), STOPMS II (p = 0.001)
Sites with significant differential expression in SP vs. HC
hsa-miR-320a CLIMB (p = 0.005), STOPMS II (p = 0.018)
hsa-miR-320b CLIMB (p = 0.002), STOPMS II (p = 0.01)
hsa-miR-320c CLIMB (p = 0.009), STOPMS II (p = 0.046)
hsa-miR-486-5p CLIMB (p = 0.023), STOPMS II (p = 0.016)
Sites with significant correlation between miRNA and EDSS
hsa-miR-337-3p CLIMB (p = 0.007), AMIR (p = 0.038), EPIC (p = 0.044)
hsa-miR-142-5p CLIMB (p = 0.049), AMIR (p = 0.023)
hsa-miR-199a-5p CLIMB (p = 0.03), AMIR (p = 0.01)
hsa-miR-330-3p CLIMB (p = 0.008), AMIR (p = 0.022)
hsa-miR-194-5p AMIR (p = 0.034), EPIC (p = 0.01)
hsa-miR-941 AMIR (p = 0.039), EPIC (p = 0.05)
Abbreviations: AMIR = AUBMC-Multiple Sclerosis Interdisciplinary Research cohort; CLIMB = Comprehensive Longitudinal Investigation of Multiple Sclerosis;
EDSS = ExpandedDisability Status Scale; EPIC = Expression/genomics, Proteomics, Imaging, and Clinical cohort; HC = healthy control;miRNA =microRNA; RR =
relapsing-remitting MS; SP = secondary progressive MS; STOPMS II = Stockholm Prospective Assessment of Multiple Sclerosis.
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differentially expressed in 2 of the 4 MS cohorts: hsa-let-7e-5p
(AMIR and STOPMS II), hsa-let-7f-5p (CLIMB and
STOPMS II), hsa-miR-486-5p (CLIMB and STOPMS II),
and hsa-miR-30e-5p (CLIMB and EPIC) (table 4).
For the comparison of RR and HC, 2 miRNAs were differ-
entially expressed in 2 of the 4 MS cohorts: hsa-let-7e-5p
(AMIR and STOPMS II) and hsa-let-7f-5p (CLIMB and
STOPMS II) (table 4). For the comparison of SP and HC,
has-miR-320a, hsa-miR-320b, hsa-miR-320c, and hsa-miR-
486-5p were differentially expressed in the CLIMB and
STOPMS II cohorts (table 4).
When comparing the 4 cohorts in terms of association with the
EDSS score, a statistically significant negative correlation with
hsa-miR-337-3pwas observed in 3 (CLIMB,AMIR andEPIC) of
the cohorts. An additional 5miRNAs (hsa-miR-142-5p, hsa-miR-
199a-5p, hsa-miR-330-3p, hsa-miR-194-5p, and hsa-miR-941)
showed a significant correlation in 2 of the cohorts (table 4).
When the prediction models from the CLIMB validation were
applied to the transportability phase cohorts, the performance of
the models was generally poor for most of the comparisons
performed. The best performance was observed in the STOPMS
II cohort for the SP vs HC comparisons (AUCROC = 0.73 for
best subset model and AUCROC = 0.81 for random forests).
hsa-miR-337-3p as a marker for disability in MS
The expression of hsa-miR-337-3p negatively correlated with
the EDSS in the discovery set of n = 85 (rs = −0.34; p = 0.0002)
and the validation phases of n = 58 (rs = −0.30; p = 0.02).9
These findings were further tested in another set of samples
obtained from the CLIMB study (reproducibility phase) and in
collaboration with 2 other international MS centers during the
transportability phase (figure 1). Results from these validation
studies confirmed that hsa-miR-337-3p is negatively correlated
with the EDSS in 3 of 4 cohorts as summarized in figure, B.
In addition, we found that in the CLIMB cohort SPMS patients
have significantly decreased (p = 0.01) expression of hsa-miR-
337-3p compared with the patients with RRMS (figure, C).
The comparison between patients with SPMS and RRMS in
the other 3 international cohorts showed a similar reduction in
the expression of hsa-miR-337-3p in patients with SPMS
compared with those with RRMS in 3 of the 4 cohorts (EPIC,
AMIR, and CLIMB) (figure e-6, links.lww.com/NXI/A63).
Discussion
In this study, we tested the differential expression of serum
miRNAs and the performance of prediction models in sam-
ples from untreated patients with MS. The study aimed at
testing both reproducibility in CLIMB and transportability in
multiple international centers. In our reproducibility phase
cohort, we validated the differential expression of hsa-miR-
484 in patients with MS as compared to HC (FDR < 0.05). In
addition, we found an excellent performance of the prediction
model including hsa-let-7c-5p and hsa-miR-452-5p discrimi-
nating MS from HC with an AUC of 0.85. hsa-miR-484 is
a known factor in the regulation of neural progenitor cells and
Figure Correlation between the Kurtzke Expanded Disability Status Scale and the relative expression of
hsa-miR-337-3p
(A) Reproducibility phase: Spearman
correlation between the Kurtzke EDSS
and the relative expression of miR-
337-3p in the CLIMB cohort. (B)
Transportability phase: Spearman
correlation between the EDSS and
the relative expression of miR-337-3p
across all MS centers. Number of
patients with MS expressing hsa-miR-
337-3p; mean MS = the mean expres-
sion value of hsa-miR-337-3p; SD MS =
the SD from the mean of the expres-
sion value of hsa-miR-337-3p. (C)
Differential relative expression of hsa-
miR-337-3p in patients with RRMS
compared with patients with SPMS in
the CLIMB cohort, using LNA-based
qPCR. Abbreviations: AMIR = AUBMC-
Multiple Sclerosis Interdisciplinary Re-
search; CLIMB = Comprehensive Lon-
gitudinal Investigation of Multiple
Sclerosis; EDSS = Expanded Disability
Status Scale; LNA = locked nucleic acid;
RR = relapsing-remitting; SP = second-
ary progressive; STOPMS II = Stock-
holm Prospective Assessment of
Multiple Sclerosis II cohort.
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its decreased expression causes dysregulated synaptogenesis
and is linked to neurodevelopmental conditions including
epilepsy, autism, and hyperactivity12; hence, its increased ex-
pression in MS patients’ sera might actually reflect the acti-
vation of neurogenesis pathways as part of an ongoing repair
process.
Although no single miRNA was identified to be differentially
expressed in all 4 cohorts when comparing SPMS vs HC, we
found that the expression levels of hsa-miR-486-5p, hsa-miR-
320a, hsa-miR-320b, and hsa-miR-320c were significantly
upregulated in at least 2 independent international cohorts
(table 4). Increased expression of hsa-miR-320a, hsa-miR-
320b, and hsa-miR-320c also appears relevant to MS patho-
physiology, and overexpression of miR-320 was found in MS
lesions.13 Multiple hsa-miR-320 targets previously reported
could be involved inMS progression and in other diseases, such
as cancer. Some of these targets includeCD71,MCL-1,MMP-9,
NRP1, HDAC4, B-catenin, and MAPK.14–21 In this regard, the
effect of hsa-miR-320 on MS pathogenesis is likely contextual,
depending on the expression levels of the particular targets and
the levels of this miRNA in specific cell types. One intriguing
target for hsa-miR-320 is the proangiogenic NRP1 in oral
cancer.17 NRP1 is highly involved in regulatory T-cell de-
velopment, and it has been reported thatNRP1 knockout mice
exhibit a more Th17-like phenotype.22 This would suggest
a pathogenic role for hsa-miR-320 in MS pathophysiology.
However, when considering the other potential targets, it
appears that hsa-miR-320 could also serve a protective role in
MS.23–29 Of interest, differential expression of hsa-miR-320 is
not unique toMS; we also found it to be significantly increased
in the sera of patients with Alzheimer disease (AD) and asthma,
whereas it was decreased in the sera of patients with amyo-
trophic lateral sclerosis (ALS) in comparison to HC samples
(unpublished data and Raheja et al30).
We discovered that hsa-miR-337-3p and hsa-miR-199a-5p
negatively correlated with patient disability (EDSS). The
correlation of hsa-miR-199a-5p expression to the EDSS was
observed in samples from 2 independent centers. The modest
negative correlation of hsa-miR-337-3p with the EDSS was
corroborated in 3 independent MS cohorts. In addition, the
expression of hsa-miR-337-3p was found to be downregulated
in patients with AD compared with healthy individuals, but was
not differentially expressed in other diseases including asthma,
rheumatoid arthritis (RA), and ALS (unpublished data). Our
recent study on the correlation of MRI parameters to circu-
lating miRNA expression also showed that the decreased ex-
pression of hsa-miR-337-3p is correlated with increased T1/T2
lesion load (Spearman correlation coefficient = −0.39; p =
0.012).31 Thus, hsa-miR-337-3p is a potential biomarker can-
didate for MS disease progression. Of interest, it has been
reported that hsa-miR-337-3p targets RAP1A in cancer.32
As RAP1A is a well-established major component of integrin
activation,33 these findings points toward a potential role of
hsa-miR-337-3p to serve as a biomarker for prediction of
therapy response to natalizumab, an α4β1-integrin inhibitor.34
Some limitations encountered in this study include sample
size, modest effect size of the reported findings, patient het-
erogeneity, and intercenter differences in patient selection
and sample preparation and storage. Although we were able to
confirm the transportability of several miRNAs in this in-
ternational multicenter study population, we were also sur-
prised that only few miRNAs were corroborated in all 4
centers. We believe that the inability to observe differences
across all cohorts is likely attributed to these aforementioned
limitations, in particular the low power of the study, especially
considering the number of multiple comparisons. At the same
time, we performed the analysis using all available samples
rather than performing an a priori power calculation to de-
termine the correct sample size. The heterogeneity of the
population can be overcome in future studies by increasing
the sample size across all comparison groups and using
a standard procedure for patient’s sample collection and
storage. A sample size of 124 would be required to have 80%
power to detect the all the differences observed in table 2
using a 2-sample t-test.
We were also unable to validate any differentially expressed
miRNAs in the RRMS population across multiple centers.
Notably, there is a higher variability in the EDSS scores of
the patients with RRMS collected from multiple centers
(table 1).
This is an attempt to examine the potential of miRNAs as
biomarkers in an international multicenter setting for the di-
agnosis and correlation with disability in MS. It is also an
attempt to build a prediction model in a validation phase after
a training phase and a discovery phase. We found a promising
candidate (hsa-miR-337-3p) to be used to identify a pro-
gression state that has great potential for translation to
a clinical setting. Altogether, our work on circulating miRNA
biomarkers is likely to help promote the development of novel
tools for noninvasive diagnosis and therapeutic prognosis
for MS.
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